IKT NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Inhibikase Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.18 USD
-6.4% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 18.5% above the Trend Line and sits at 70.8% of its 52-week range. The latest completed week returned -6.4%, after a 9.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 62 out of 100
Latest Close 2.18 USD 31 Jul 2026
1W Return -6.4% latest completed week
4W Return 9.5% short-term follow-through
12W Return 5.8% quarterly tape
Trend Breadth 44.2% 23 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • The trend backdrop is active with a 6-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -6.4% Latest completed week; four-week move 9.5%. Indicator stack 45/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 56/100 51 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 18.5% above the Trend Line and sits at 70.8% of its 52-week range. The latest completed week returned -6.4%, after a 9.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6512-week average 0.60

12-week confirmation

Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.65Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 9.5% over four weeks, 5.8% over 12 weeks, and 43.4% over one year. The current trend has remained active for 6 consecutive weeks.

Performance by holding period

1W-6.4%
4W9.5%
12W5.8%
26W45.3%
52W43.4%
Active trend streak6 weeks
Active weeks in one year23
Trend breadth44.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.05Latest activity-pressure read.
Pressure change1221.9%Four-week change in activity pressure.
Leadership14.01Latest relative-leadership reading.
RS change3374.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength56/100Blend of value, momentum, and quality. Underlying universe rank 45; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality51/100Profitability and accounting quality. Underlying universe rank 50; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-11.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-35.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-30.2%
Net share repurchases relative to market value.
Shareholder yield
-30.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 51 relevant articles.

15 positive · 33 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-13.8%Distance below the 52-week high.
13-week volatility7.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher17 of 269 weeks finished lower.
Best week+16.5%Week of 27 Feb.
Worst week-16.0%Week of 15 May.
Latest week-6.4%Week of 31 Jul.

Shape of recent returns

Strong gains11
Modest gains6
Flat weeks0
Modest losses2
Sharp losses7
Recent vol7.1%13-week weekly-return volatility.
Base vol7.8%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew6.9% / -5.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape61/100

Trend, activity pressure, participation, and risk combine to a 61/100 tape read.

 Indicator analysis57/100

Latest 12-week confirmation: trend 9/12, activity pressure 6/12, relative leadership 5/12.

Activity pressure 0.65; No reversal markers Factors52/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93; Small Cap Core rank 53 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 51 relevant articles.

RA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants Insiders6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.18 USD-6.4%1.84 USD1.84 USD1.0514.012.4MOn
24 Jul 20262.33 USD10.4%1.83 USD1.84 USD1.0022.886.1MOn
17 Jul 20262.11 USD3.4%1.82 USD1.84 USD0.789.707.7MOn
10 Jul 20262.04 USD2.5%1.81 USD1.85 USD0.351.474.0MOn
3 Jul 20261.99 USD4.2%1.79 USD1.85 USD-0.090.403.6MOn
26 Jun 20261.91 USD4.4%1.78 USD1.86 USD-0.55-3.226.5MOn
19 Jun 20261.83 USD9.6%1.76 USD1.87 USD-0.81-11.603.2MOff
12 Jun 20261.67 USD2.5%1.75 USD1.88 USD-0.83-17.572.8MOff
5 Jun 20261.63 USD-6.9%1.75 USD1.90 USD-0.65-18.373.0MOff
29 May 20261.75 USD3.6%1.74 USD1.91 USD-0.12-17.101.7MOn
22 May 20261.69 USD-2.3%1.73 USD1.93 USD0.13-18.455.2MOn
15 May 20261.73 USD-16.0%1.73 USD1.94 USD0.36-16.143.1MOn
8 May 20262.06 USD7.9%1.72 USD1.95 USD0.48-1.403.3MOn
1 May 20261.91 USD1.6%1.71 USD1.96 USD0.14-4.313.2MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.